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Introduction
Dihydropyridine (DHP)-derivative calcium channel blockers (CCBs) 
are widely used as first-line antihypertensive agents.
1) The currently 
known voltage-gated calcium channel subtypes include L-, T-, N-, 
P/Q-, and R-types.
2) Efonidipine, a DHP-derivative CCB, has been pro-
ven to exert a blocking effect on L- type as well as T-type calcium ch-
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Results: The mean 24-hour SBP and HR decreased significantly after treatment. The diurnal to nocturnal SBP ratio in dipper-type hyper-
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annels.
3) Recently, multiple actions of the T-type calcium channel 
have been noted, including regulation of the microvascular tone and 
firing rate of sinoatrial nodal cells in the heart,
4)5)7) control over burst 
firing of thalamic neurons in relation to absence epilepsy,
5)6) reduc-
tion in proteinuria and plasma aldosterone levels,
2)8) and prevention 
of sudden death in mice with heart failure.
9) Efonidipine has been 
clinically used in Japan as an antihypertensive agent for its mild 
persistent hypotensive effect. Despite the above mentioned phar-
macological interests in efonidipine, its hypotensive action and ef-
fect on heart rate over an entire day have not been fully investigat-
ed. Patient with nocturnal hypertension have a worse prognosis than 
the ones with a normal circadian rhythm of blood pressure. Changes 
in the circadian blood pressure profile after the administration of an 
antihypertensive agent have direct implications on evaluating the 
quality of anti-hypertensive drug therapy.
10)
In the present study, we examined drug-induced circadian ch-
anges in 24-hour systolic blood pressure (24-hour SBP) and heart 
rate (24-hour HR) obtained from 24-hour ambulatory blood pres-
sure monitoring (24-hour ABPM) before and after treatment with 232  L- and T-CCB and Hypertension 
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efonidipine in patients with essential hypertension. Circadian vari-
ations of above parameters were expressed as a function of time. 
As the results, a quantitative analysis of antihypertensive action of 
the drug throughout the day can lead a new chronopharmacologi-
cal approach on antihypertensive drug therapy.
Subjects and Methods
Participants and study design
A total of forty-five Japanese patients with hypertension (22 men 
and 23 women) who first visited the out-patient clinic of Showa 
University Fujigaoka Hospital, Yokohama, Japan, participated in this 
study. This group consisted of de novo hypertensive patients with 
an average age of 62.2±10.1 years, and all participants had either 
Grade 1 or Grade 2 essential hypertension according to the Euro-
pean Society of Cardiology guidelines for the management of arte-
rial hypertension.
1) The office SBP were between 140 and 179 mm Hg 
and diastolic blood pressure (DBP) were between 90 and 109 mm 
Hg, measured at least twice during a 2 week period; these mea-
surements were performed during out-patient checkups after the 
patients were seated for at least 10 minutes. Conventional office BP 
measurements were always obtained by the same investigator who 
were technical cardiologists in order to avoid observer bias. Patients 
with secondary arterial hypertension, renal insufficiency, uncon-
trolled diabetes, and cardiovascular disorders including angina pec-
toris, congestive heart failure, chronic arrhythmia (e.g., persistent 
atrial fibrillation), or previous myocardial infarction, were excluded. 
After obtaining informed consent from the participants including 
the patients volunteer, the patients underwent 24-hour ABPM with-
out treatment with antihypertensive drugs. After 24-hour ABPM, 
the subjects received 40 mg of efonidipine hydrochloride [5-(5,5-di-
methy-l,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-
4-(3-nitrophenyl)-3-pyridinecarboxylic acid, 2-{phenyl(phenyl-me-
thyl)amino} ethyl ester, P-oxide, hydrochloride]; (Nissan Chem. Int. 
Ltd., Tokyo, Japan), which was administered once daily immediately 
after waking.
11) This drug has been known as an L- and T-type CCB 
that exerts long-lasting antihypertensive action.
11)12) If the attending 
physician determined that the voluntary blood pressure levels had 
normalized during the follow-up period after treatment, a second 
24-hour ABPM was performed. If either the voluntary blood pres-
sure or second 24-hour ABPM had not normalized for 3 months, 
efonidipine was replaced with another antihypertensive agent. The 
average follow-up period was 5.2±1.7 months. The ethics commit-
tee of Showa University Fujigaoka Hospital approved the protocol 
of this study.
24-hour ambulatory blood pressure monitoring assessment 
and actigraphy
The SBP and HR of each patient were automatically measured 
every 30 minutes for 24 consecutive hours from 9:00 a.m. to next 
9:00 a.m. on the following day, using a cuff-oscillometric, multi-
sensor ABPM device (TM-2425; A & D Co. Ltd., Tokyo, Japan), which 
simultaneously recorded blood pressure, electrocardiogram and phy-
sical activity during the entire 24-hour of a routine workday. The 
device satisfied the criteria of the Association for the Advancement 
of Medical Instrumentation and the British Hypertension Society. 
Previous reports have described the detailed features as well as the 
usefulness of this device in clinical hypertension research.
13)14) The 
recording method using this device has authorized by related pa-
pers.
14) The International Society of Hypertension recommends us-
ing recording intervals of 15- to 20 minutes during daytime and in-
tervals of 30 minutes at night for 24-hour ABPM. However, most 
Japanese patients, particularly women, are unwilling to undergo SBP 
recording at short intervals (15- to 20 minutes) and decline to un-
dergo 24-hour ABPM for a second time. Consequently, the SBP and 
HR were measured every 30 minutes. Hermida et al.’s
15) criteria were 
used to evaluate whether the ABPM data series was valid for analy-
sis. They commented that 24 hour-SBP data series were not consid-
ered valid for analysis if more than 30% of the measurements were 
missing, if data were missing for an interval of >2 hours, if data 
were obtained while patients had an irregular rest-activity sched-
ule, or if the nighttime sleep period was 12 hours during ABPM. 
Eight patients who did not fulfill the criteria were excluded from this 
study. Actigraphy data and diary records were used to define wake-
fulness and sleep spans. 
Diurnal to nocturnal systolic blood pressure ratio
In order to evaluate the effects of efonidipine on circadian rhy-
thm, the diurnal and nocturnal mean SBP values (D/N SBP ratio) 
were studied. The average time at which the participants went to 
sleep in this study was 10:40 p.m., and the average time at which 
they woke up was 6:27 a.m. Accordingly, the diurnal period was 
derived as extending from 7:00 a.m. to 10:00 p.m., and the nocturnal 
period as extending from 10:30 p.m. to 6:30 a.m. The D/N SBP ratio 
was defined as the percentage decrease in SBP during nocturnal rest, 
relative to the diurnal mean SBP, and calculated using the follow-
ing equation, (diurnal SBP mean-nocturnal SBP mean)/diurnal SBP 
mean×100.
15) 
If the D/N SBP ratio ranged from 10% to 20%, the 24-hour SBP 
mode was defined as dipper-type hypertension. If it ranged from 
0% to 10%, the 24-hour SBP mode was defined as non-dipper-type 
hypertension.
16)233 Masae Komukai, et al.
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The best-fit curve 
A commercial computer program (MemCalc; Suwa Trust Co. Ltd., 
Tokyo, Japan) was applied to generate the best-fit curve for chang-
es in the 24-hour SBP or HR (ΔSBP, ΔHR) every 30 minutes before 
and after administration of the drug. The best-fit curve was used to 
provide a more accurate assessment of the response to the action 
of the drug throughout a day. A detailed description of the program 
has been previously provided.
17) This program primarily utilizes the 
maximum entropy method (MEM), which is applied to detect time 
structures in time-series data, and the non-linear least squares me-
thod (LSM) to provide a best-fit periodic function. Using this method, 
the pharmacokinetic characteristics of the drug can be expressed 
as precise numerical values. The median value shows the midline 
estimating statistic of rhythm (MESOR), which is the 24-hour aver-
age value of the rhythmic waveform function fitted to the data.
Statistical analysis
Comparison of the 24-hour SBP and HR values before and after 
treatment with the drug was performed using a paired t-test (2-sid-
ed). Data are shown as the mean±standard deviation. A value of 
p<0.05 was considered significant.  
Results
The demographic characteristics and office blood pressure read-
ings of the 45 subjects are shown in Table 1. All patients received an 
L- and T-CCB (efonidipine; 40 mg/day) after waking. The mean of-
fice SBP and DBP values of the participants were 165.1±11.0 mm 
Hg and 96.9±7.5 mm Hg, respectively. After treatment with efoni-
dipine, the mean office SBP and DBP significantly dropped to 
132.6±7.6 mm Hg and 80.1±6.8 mm Hg (p<0.01), respectively, and 
they were judged to be stable by the attending physician in the 
outpatient clinic. 
According to the 24-hour ABPM assessment of Hermida et al.,
15) 
24-hour ABPM data series were not considered valid for analysis 
when more than 30% of the measurements were missing, and ad-
ditionally when data were missing for an interval of >2-hour. As a 
result, 8 of the original 45 patients were eliminated from the study, 
and 24-hour ABPM data from 37 of the 45 patients were used in 
this study.
The 24-hour mean values of blood pressure and HR obtained by 
24-hour ABPM are shown in Table 2. The 24-hour mean SBP, and 
DBP dropped from 152.0±14.7 to 142.7±13.9 mm Hg (p<0.01) and 
from 90.9±10.9 to 85.9±9.6 mm Hg (p<0.01), respectively. The 24-
hour mean HR dropped from 72.9±6.5 to 67.4±6.6/min (n=37, 
p<0.01). In dipper-type hypertension cases (n=32), the 24-hour 
mean SBP and DBP dropped from 151.0±14.1 to 142.6±14.3 mm 
Table 1. Characteristics and demographic data of the enrolled patients
Patients (n) 45
Age (years) 61.6±9.9
Body mass index (kg/m
2) 24±3
Gender (male/female) 22/23
Follow-up periods (months) 5.2±1.7
Before treatment
   Mean office SBP (mm Hg) 165.1±11.0
   Mean office DBP (mm Hg) 96.9±7.5
   Mean office PR (beats/min) 75.2±5.6
After treatment
   Mean office SBP (mm Hg) 132.6±7.6*
   Mean office DBP (mm Hg) 80.1±6.8*
   Mean office PR (beats/min) 73.6±4.2
Night-time is illustrated by closed transverse bars. All values are the mean± 
SD. *p<0.01: before vs. after treatment. DBP: diastolic blood pressure, SBP: 
systolic blood pressure, PR: pulse rate
Table 2. Changes in mean 24-hour SBP, DBP, and HR before and after treatment with efonidipine
SBP (mm Hg) DBP (mm Hg)            HR (per minute)
Before After Before After Before After
Total (n=37)
24-hour mean pressure 152.0±14.7 142.7±13.9
† 90.9±10.9 85.9±9.6
†
24-hour mean HR 72.9±6.5 67.4±6.6
†
Dipper (n=32)
24-hour mean pressure 151.0±14.1 142.6±14.3
† 90.6±10.2 86.3±9.5
†
24-hour mean HR 72.2±5.6 70.1±6.1
Non-dipper (n=5)
24-hour mean pressure 158.8±18.7 143.9±12.9 92.8±16.0 83.4±11.1
24-hour mean HR 77.1±9.6 65.5±9.4*
All values are the mean±SD. Two sided t-test; *p<0.05; 
†p<0.01; before vs. after drug administration. DBP: diastolic blood pressure, HR: heart rate, SBP: 
systolic blood pressure234  L- and T-CCB and Hypertension 
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Hg (p<0.01) and from 90.6±10.2 to 86.3±9.5 mm Hg (p<0.01), re-
spectively. The 24-hour mean values of HR were reduced slightly 
in dipper cases, but in non-dipper-type hypertension cases (n=5) 
these were significantly reduced from 77.1±9.6 to 65.5±9.4/min 
(p<0.05).
In order to assess the actions of efonidipine on the 24-hour SBP 
and HR, the average SBP and HR during a 24-hour period were plot-
ted every 30 minutes throughout the day for patients whose mean 
SBP during the 24-hour period fell by 5 mm Hg or more after treat-
ment with the drug (n=29) (Fig. 1A). The average diurnal SBP (7:00 
a.m. to 10:00 p.m.) dropped significantly (p<0.05 or less), and aver-
age nocturnal SBP (10:30 p.m. to 6:30 a.m.) dropped slightly. Diur-
nal average HR decreased slightly, but no changes were seen in 
nocturnal average HR. Similarly, the average SBP and HR for subjects 
whose mean 24-hour SBP did not fall after treatment with the drug 
(n=8) are illustrated in Fig. 1B. In contrast to Fig. 1A, this graph 
shows that the average diurnal SBP after treatment was tended to 
be higher than that prior to treatment with the drug, and the aver-
age HR slightly decreased throughout the day. Three of these 8 pa-
tients were coincidentally under increased stress due to a busier 
work schedule than usual or due to a period of sleeplessness at the 
time of the second 24-hour ABPM that proved out the documen-
tations of their diary during the examination consequently, their SBP 
values were unexpectedly elevated. These patients were followed 
without a change in the drug regimen. The remaining 5 patients 
were treated with efonidipine plus either an α, β-blocker (carve-
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Fig. 1. Alterations in systolic blood pressure (SBP) and heart rate (HR) over 24-hour periods before and after efonidipine administration. A: each 30-min-
ute average value of SBP and HR over a 24-hour time period, measured in patients whose average 24-hour SBP fell by 5 mm Hg or more after administra-
tion of the drug (n=29). B: each 30-minute average value of SBP and HR over a 24-hour period measured, in patients whose average 24-hour SBP did not 
fall after administration of the drug (n=8). The gray shaded horizontal bars in each graph represent the average nocturnal period (10:30 p.m. to 6:30 a.m.) 
in this study.  : average systolic blood pressure before drug administration,  : average systolic blood pressure after drug administration,  : aver-
age heart rate before drug administration,  : average heart rate after drug administration. Each value represents an average value±SD. *p<0.05, 
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dilol; 5-10 mg/day) or an angiotensin II receptor blocker (candesar-
tan; 8 mg/day). The 24-hour SBPs of all 37 patients were normaliz-
ed after approximately 6 months.
Changes in the mean diurnal SBP (7:00 a.m. to 10:00 p.m.) and the 
mean nocturnal SBP (10:30 p.m. to 6:30 a.m.) are illustrated in Fig. 2. 
The mean diurnal SBP decreased from 165.0±12.4 to 145.2±13.5 
mm Hg after treatment with the drug in the dipper cases (p<0.05) 
as show in upper left graphs. In the non-dipper cases, mean noctur-
nal SBPs dropped significantly from 159.1±15.5 to 137.3±19.2 mm 
Hg (p<0.01) as show in upper right graphs. The D/N SBP ratios in 
both groups are illustrated in the lower graphs. The D/N SBP ratio 
reduced from 16.7±6.1% to 8.3±9.8% in dipper cases (p<0.05), 
and increased from 2.3±2.9% to 7.7±5.1% in non-dipper cases (p< 
0.01), because the SBP drop was more marked during nighttime in 
the latter group. 
To perform more accurate assessments of the antihypertensive 
actions of the drug, ΔSBP and ΔHR were measured in each patient 
at 30-minute intervals during the 24-hour period before and after 
treatment with the drug. After obtaining the average ΔSBP and 
ΔHR every 30 minutes in dipper and non-dipper cases, their best-fit 
curves were generated using MEM-LSM. Fig. 3 shows the best-fit 
curves of the average ΔSBP and ΔHR, which indicate the antihy-
pertensive effect of the drug throughout the day. The average ad-
ministration time of the drug after waking was 6:30 a.m., as indi-
cated by the thick arrows. This figure shows the superimposed 
curves of the average 24-hour ΔSBP and ΔHR in both dipper and 
non-dipper cases. As shown in the upper graph of this figure, the 
median values of the periodic function for the average 24-hour 
ΔSBP (MESOR) were -9.1 mm Hg in dipper cases and -9.2 mm Hg in 
non-dipper cases. In the dipper cases, the antihypertensive effect 
was maximized at 11:30 a.m., 5.0-hour after administration of the 
drug. During this time, the mean drop in SBP was 4.7 mm Hg/h. The 
antihypertensive effect showed maximum attenuation at 12:30 
a.m., 19.0 hours after administration of the drug, during which the 
mean rise in SBP was 2.1 mm Hg/h. The non-dipper cases showed 
ΔSBP changes opposite to those seen in dipper cases from noon to 
night-time. The rise in SBP in the morning was suppressed in both 
dipper and non-dipper cases. The lower graph of Fig. 3 illustrates 
the changes in the average 24-hour ΔHR before and after treatment 
with the drug. Median 24-hour ΔHR was -2.3/min in dipper cases, 
and -5.4/min in non-dipper cases. In the dipper cases, a continuous 
reduction in ΔHR was seen from 3.5 to 23 hours after administra-
tion of the drug. In the non-dipper cases, ΔHR values were unsta-
ble and showed a decrease from day-time to midnight, but were 
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elevated after waking (6:30 a.m.). The change in ΔHR seemed to 
occur without correlation to the passage of time from the admini-
stration of the drug.
Discussion
In this study, best-fit curves were used to analyze circadian ch-
anges in ΔSBP and ΔHR before and after efonidipine monotherapy 
upon awakening. As demonstrated in Fig. 3, maximum antihyper-
tensive action was observed at 5 hours after the morning dosing, 
and this action was long-lasting with a duration of 11-12 hours. In a 
pharmacokinetic study in humans, the Tmax and Cmax of efonidipine 
were 2.5±0.3 hours, and 19.0±6.0 ng/mL, respectively.
18) The biliary 
system was the main route of elimination for this drug.
18) In experi-
ments with spontaneously hypertensive rats, the hypotensive ac-
tion of NZ-105 (efonidipine; 5 mg/kg) peaked at 3 hours and lasted 
for more than 9 hours, while that of nicardipine (5 mg/kg) peaked 
at 0.5 hours and lasted for 3 hours.
11) A pharmacodynamic study 
showed that the binding affinity of 
3H-efonidipine for DHP recep-
tors in rabbit aortic microsomes was 5.7-fold less potent than that 
of 
3H-nitrendipine, and the dissociation constant (Kd) of 
3H-efoni-
dipine (4.48 nM) was approximately 6 times larger than that of 
3H-
nitrendipine (0.79 nM).
19) On the basis of these experimental results, 
efonidipine has been considered to belong to the group of slow-on-
set and long-lasting CCB. In the present study, efonidipine did not 
fully demonstrate the typical characteristics of long-lasting CCBs, 
an effect that may be attributed to a major difference in its dosing: 
5 mg/kg in experiments vs. 40 mg once daily in clinical medication. 
The hypotensive action of efonidipine peaked at 5 hours after ad-
ministration. The rate of the drug’s hypotensive effect was 4.7 mm 
Hg/h, and it slowly recovered at a constant rate (2.1 mm Hg/h) over 
12 hours in dipper cases, which appears to be a characteristic prop-
erty of efonidipine. The D/N SBP ratio significantly decreased (from 
16.7±6.1% to 8.3±9.8%) after treatment with efonidipine, chiefly 
due to the fall in diurnal SBP in dipper cases. In previous studies, a 
once-daily morning dose of typical long-lasting CCBs (amlodipine, 
nifedipine GITS, nisoldipine ER, etc.) was shown to be equally ef-
fective in reducing the mean 24-hour SBP level. The D/N SBP ratios 
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before and after treatment were 11.2% and 11.0% for nifedipine 
GITS, and 5.1% and 5.7% for amoldipine.
20)21) Thus, the hypotensive 
effect of efonidipine on nocturnal SBP reduction in dipper cases was 
weaker than that of typical long-lasting drugs. On the other hand, 
an interesting hypotensive effect of efonidipine that was not time-
dependent was observed in non-dipper cases; however, this result 
was not conclusive due to the small number of cases. Further study 
consisting of a larger sample size is needed to better understand 
these phenomena.
The MorBidity-mortality EvAIUaTion of the If inhibitor ivabradine 
in patients with coronary disease and left ventricULar dysfunction 
(BEAUTIFUL) study demonstrated that elevated HR is associated 
with an increased risk of cardiovascular mortality.
22) The mean reduc-
tion in 24-hour HR after treatment with a long-lasting CCB in pre-
vious studies was smaller than that observed in this study, and in 
most studies it did not significantly change, even when a long-last-
ing L- and N-type CCB was administered.
14) A recent study demon-
strated that resting HR decreased significantly after treatment with 
efonidipine.
23) In the present results, the mean 24-hour HRs de-
creased significantly (p<0.01). A well-known disadvantage of the 
hypotensive effect of L-type CCBs is that it is accompanied by re-
flex tachycardia.
22) Previous studies have noted that the hypoten-
sive effect of efonidipine is accompanied by less or no reflex tachy-
cardia.
24) The direct suppression of phase 4 depolarization (pace-
maker potential) in the sinus node, which is produced by the bloc-
kage of these channels, is likely to be a cause of the decrease in 24-
hour HR.
12) The slow, constant recovery of SBP after the initial drop 
may also contribute to HR reduction. These properties of efonidip-
ine may be related to the present results, in that the changes in 
ΔHR during 24 hours were not dependent on administration-time. 
In summary, the antihypertensive actions of efonidipine were 
characterized by an administration time-dependent fall in 24-hour 
SBP (4.7 mm Hg/h) and a long-lasting recovery of the decrease in 
SBP at a constant rate (2.1 mm Hg/h), in addition to a non-adminis-
tration time-dependent decrease in 24-hour HR. To understand the 
precise action of L- and T-type CCB, further clinical studies will be 
needed.
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